A Phase 2 interventional study of Myofascial Pain and Orofacial Bone Pain in Chronic Postsurgical Pain, Chronic Post Cancer Surgery Pain and Chronic Post Operative Pain, sponsored by Shaukat Khanum Memorial Cancer Hospital & Research Centre. Recruiting at 1 site in Pakistan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Shaukat Khanum Memorial Cancer Hospital & Research Centre · Phase 2, Interventional, and Treatment
The goal of this clinical trial is to find out whether a phenotype-based pain management approach can reduce chronic pain in adults (18 years and older) who have completed curative treatment for head and neck cancer and continue to experience chronic post-treatment pain.
The main questions it aims to answer are:
Participants will:
5,265 studies on the registry are indexed under Pain, Postoperative; 1,165 are open to participants now.
This study's planned enrollment of 40 is below the median of 75 across 4,496 interventional studies indexed under Pain, Postoperative.
Browse Pain, Postoperative studies →Shaukat Khanum Memorial Cancer Hospital & Research Centre is the lead sponsor of 25 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Treatment given based on the clinical phenotype
Other: Myofascial Pain · Other: Orofacial Bone Pain · Other: Neuralgia Pain · Other: Burning Pain · Other: Persistent Pain
Participants with myofascial pain disorder will initially receive muscle relaxants, such as tizanidine (up to 8 mg per day), cyclobenzaprine (up to 30 mg per day), or amitriptyline (up to 25 mg per day). When the reported pain intensity is 7 or more out of 10, these participants will additionally undergo masticatory or cervical trigger point injections.
Participants identified with orofacial bone pain disorder who report a pain intensity of less than 7 out of a possible 10 on the Numeric Verbal Rating Scale (NVRS) will receive non-opioid analgesics, including acetaminophen and non-steroidal anti-inflammatory medications. In cases where the pain intensity is 7 or more, participants will be offered targeted nerve blocks. These blocks will be performed along the sensory nerves supplying the affected region to provide localized pain relief.
Participants classified with neuralgia will be treated with pregabalin (up to 600 mg per day) or carbamazepine (up to 1200 mg per day). Nerve blocks will be considered for those experiencing pain of 7 or more out of 10. In summary, participants with persistent pain disorder, burning disorder, or neuralgia phenotypes who present with pain intensity scores of 7 or higher will be given nerve blocks around the sensory nerves corresponding to the region of pain.
Participants with burning pain will receive pregabalin (up to 600 mg per day), carbamazepine (up to 1200 mg per day), or clonazepam (up to 2 mg per day), and if their pain intensity meets or exceeds 7 out of 10, nerve blocks will similarly be provided to target the sensory pathways involved.
Those diagnosed with persistent pain disorder will be treated with either amitriptyline (up to 25 mg per day) or pregabalin (up to 600 mg per day). Participants in this group who report pain intensity of 7 or more will also be offered nerve blocks administered at sites corresponding to the involved sensory distribution.
Pain Reduction
A phenotype-based pain management model will provide significant pain relief to participants at one month, defined as at least a 75 percent decrease from average baseline pain
Time frame: From enrollment to the end of treatment at 4 weeks
Safety Profile
Discontinuation of assigned phenotype-based therapy due to adverse events by four weeks is 10 percent or less.
Time frame: From enrollment to the end of treatment at 4 weeks
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD will be shared with the journal at the time of publication. To ensure the confidentiality of subject information, each subject enrolled will be assigned a unique serial number.
Supporting information: Statistical analysis plan
Time frame: Approximately data will be available from 1 March 2027 (at the time of publication) till 5 years after the publication of the article (1 March 2031).
Access criteria: Researchers with methodologically sound proposals aimed to advance the field of pain medicine.
Started Jul 2026 (actual). Primary completion is estimated for Jan 2027, 6 months after the start.
Of 89 non-industry phase 2 interventional studies under Pain, Postoperative, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's planned 6 months is below that.
Counting every sponsor, half of 137 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shaukat Khanum Memorial Cancer Hospital & Research Centre